PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.28%
Negative revenue growth while META stands at 25.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
5.17%
Gross profit growth under 50% of META's 26.28%. Michael Burry would be concerned about a severe competitive disadvantage.
25.26%
EBIT growth 50-75% of META's 38.73%. Martin Whitman would suspect suboptimal resource allocation.
25.26%
Operating income growth at 50-75% of META's 38.73%. Martin Whitman would doubt the firm’s ability to compete efficiently.
32.63%
Net income growth under 50% of META's 172.88%. Michael Burry would suspect the firm is falling well behind a key competitor.
29.41%
EPS growth under 50% of META's 222.95%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
37.50%
Diluted EPS growth under 50% of META's 222.95%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.48%
Share reduction more than 1.5x META's 9.95%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.50%
Diluted share reduction more than 1.5x META's 3.55%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
16.61%
OCF growth under 50% of META's 172.40%. Michael Burry might suspect questionable revenue recognition or rising costs.
16.51%
FCF growth under 50% of META's 511.39%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
4936.71%
10Y revenue/share CAGR above 1.5x META's 29.36%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
158.36%
5Y revenue/share CAGR above 1.5x META's 29.36%. David Dodd would look for consistent product or market expansions fueling outperformance.
90.72%
3Y revenue/share CAGR above 1.5x META's 29.36%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
160.21%
5Y OCF/share CAGR above 1.5x META's 23.26%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
64.64%
3Y OCF/share CAGR above 1.5x META's 23.26%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
4495.38%
Positive 10Y CAGR while META is negative. John Neff might see a substantial advantage in bottom-line trajectory.
125.74%
Positive 5Y CAGR while META is negative. John Neff might view this as a strong mid-term relative advantage.
40.81%
Positive short-term CAGR while META is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
198.26%
5Y equity/share CAGR above 1.5x META's 121.48%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
91.85%
3Y equity/share CAGR at 75-90% of META's 121.48%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.94%
Our AR growth while META is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-18.28%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
4.53%
Positive asset growth while META is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
4.91%
Positive BV/share change while META is negative. John Neff sees a clear edge over a competitor losing equity.
-10.78%
We’re deleveraging while META stands at 161.20%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-12.49%
Our R&D shrinks while META invests at 21.72%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.96%
We cut SG&A while META invests at 15.05%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.